NFKB1 and cancer: Experimental data indicate that small molecule inhibition of the RELA-BRD4 interaction offers promise for the disruption of pathological NFκB signaling in cancer, a process which has been attributed to the inability of cancer cells to homeostatically control NFκB function [35].